NIH UG3/UH3 Phased Cooperative Agreement – Feasibility First, Implementation Second
The NIH UG3/UH3 Phased Cooperative Agreement mechanism supports translational, clinical, behavioral, and implementation science research that requires a structured feasibility phase before progressing to full-scale execution. The UG3 phase provides milestone-driven support for proof-of-concept, feasibility testing, early clinical infrastructure development, pilot implementation, regulatory preparation, and operational readiness. If milestones are successfully met, the project transitions into a UH3 phase, which supports full implementation, optimization, scalability, multi-site coordination, or broader clinical validation.
This phased structure is ideal for multi-site clinical studies, translational innovations, biomedical technology development programs, early diagnostic or therapeutic pipelines, implementation science research, and health system intervention programs where upfront feasibility testing is essential before committing significant resources. Unlike standard R-series grants, UG3/UH3 awards operate as cooperative agreements, meaning NIH program staff remain actively involved in oversight, milestone evaluation, strategic refinement, and project integration across participating centers or partners.
Eligibility
UG3/UH3 awards may be submitted by:
U.S. universities and academic medical centers
Nonprofit research organizations
For-profit biotechnology or data science companies
Foreign institutions, depending on FOA requirements
Consortia or multi-institutional networks, when appropriate
Applicants must demonstrate strong organizational capacity, clinical or translational infrastructure, regulatory readiness, and team expertise, along with a clear operational plan for feasibility execution and later-phase expansion.
Milestones and Transition Requirements
A defining feature of the UG3/UH3 mechanism is the milestone process. UG3 applications must include:
Clear feasibility aims and quantitative milestones
Realistic timelines and operational risk mitigation
Criteria for advancing into UH3 implementation
Plans for early-stage coordination, recruitment, regulatory submissions, protocol refinement, or laboratory validation
NIH program staff carefully review milestone attainment before approving UH3 activation.
Review Considerations
Reviewers evaluate:
The feasibility of the UG3 phase
The strength of milestone definitions and contingency planning
The qualifications of the investigative team
Institutional resources and multi-site capacity
The scientific, clinical, or public health impact of full UH3 implementation
The suitability of the cooperative agreement structure
Successful applications demonstrate scalable vision, strong feasibility documentation, meaningful innovation, and disciplined project management.
How ScienceDocs Helps
ScienceDocs supports UG3/UH3 applicants with:
Milestone architecture and feasibility framework design
Clinical or translational implementation planning
Regulatory pathway and operational readiness documentation
Full proposal writing, integration, and strategic refinement
To request expert UG3/UH3 support, visit:
https://www.sciencedocs.com/quotes